Drugs / CYT-500 177LU
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00441571 | Feb 2007 → ? | metastatic prostate carcinoma | Cytogen Corporation | Unknown | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CYT-500 177LU | ChEMBL registry synonym — accepted as the source's own label CHEMBL2109553 ↗ |
| Known as | 177Lu-CYT-500 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00441571 ↗ |
| Known as | 177Lu-meO-DOTA-7E11 | “A Phase 1 Study of Radiolabeled Monoclonal Antibody 7E11-C5.3(177Lu-meO-DOTA-7E11;CYT-500) in Patients With Progressive Androgen-Independent Prostate Cancer” NCT00441571 ↗ |
| Known as | 7E11-C5.3 | “A Phase 1 Study of Radiolabeled Monoclonal Antibody 7E11-C5.3(177Lu-meO-DOTA-7E11;CYT-500) in Patients With Progressive Androgen-Independent Prostate Cancer” NCT00441571 ↗ |
| Known as | CYT-500 | “A Phase 1 Study of Radiolabeled Monoclonal Antibody 7E11-C5.3(177Lu-meO-DOTA-7E11;CYT-500) in Patients With Progressive Androgen-Independent Prostate Cancer” NCT00441571 ↗ |
| Modality | Monoclonal antibody | “Radiolabeled Monoclonal Antibody” NCT00441571 ↗ |
| Target | FOLH1 | “Glutamate carboxypeptidase II binding agent” CHEMBL2109553 ↗ |